Breast Cancer
Conference Coverage
HDAC/aromatase inhibitor combo shows promise for HR+/HER2- advanced breast cancer
MUNICH – Chidamide + exemestane combination therapy increased PFS by about 4 months, compared with exemestane...
Conference Coverage
PALOMA-3: Overall survival better for endocrine-sensitive patients only
MUNICH –
Conference Coverage
Finally, immunotherapy shows benefit in TNBC
MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...
Conference Coverage
Genotype-driven dosing reduces 5-FU, capecitabine toxicity
MUNICH – Clinic-based screening for four common variants and dose-adapted therapy reduced severe fluoropyrimidine-associated toxicity.
News
Talazoparib approved for HER2-negative advanced breast cancer
The
Feature
Tech-based cancer company raises access concerns
Oncologists say a new company that aims to link patients with cancer care and clinical trials through technology has both positives and negatives...
Conference Coverage
ESMO 2018 to highlight research on advanced breast cancer
...
Conference Coverage
MBC care causes more money problems for uninsured – but more financial stress for the insured
The uninsured more often reported material burdens; the insured reported more worry, distress, and frustration.
From the Journals
Investigators identify 21 genomic “hotspots” in breast cancers
A previously identified chromosomal translocation may be the critical initiating event in some breast cancer subtypes.
Conference Coverage
Breast cancer risk in type 2 diabetes related to adiposity
Women with type 2 diabetes mellitus have a moderately increased risk of breast cancer that appears to be mainly caused by adiposity, not diabetes...
Conference Coverage
Breast cancer patients getting unnecessary scans against recommendations
PHOENIX – Despite ASCO recommendations, many patients with early-stage breast cancers at low metastasis risk have undergone imaging tests for...